Evidence map›Paper›PMID 35002881›Full record

ReviewFrontiers in psychology2021

What Do Placebo and Nocebo Effects Have to Do With Health Equity? The Hidden Toll of Nocebo Effects on Racial and Ethnic Minority Patients in Clinical Care.

Hailey E Yetman, Nevada Cox, Shelley R Adler, Kathryn T Hall, Valerie E Stone

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in psychology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Placebo-resistant gut bacteria:Frontiers in cellular and infection microbiology · 2024
    Trial
  3. Article
  4. Placebo and nocebo effect in pain.Handbook of clinical neurology · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Hailey E YetmanDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Nevada CoxPenn State College of Medicine, Hershey, PA, United States.
Shelley R AdlerOsher Center for Integrative Health, University of California, San Francisco, San Francisco, CA, United States.
Kathryn T HallDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Valerie E StoneDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Brigham and Women's Hospital · USHarvard University · USPenn State Milton S. Hershey Medical Center · USUniversity of California, San Francisco · US

Funding

Epidemiological, pharmacogenomic and clinical impact of catechol-O-methyltransferase on cardiovascular diseaseK01HL130625 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HALL, KATHRYN TAYO · 2016 to 2021
$921k
NHLBI NIH HHS K01 HL130625
6 · The paper itself

Abstract

A placebo effect is a positive clinical response to non-specific elements of treatment with a sham or inert replica of a drug, device, or surgical intervention. There is considerable evidence that placebo effects are driven by expectation of benefit from the intervention. Expectation is shaped by a patient's past experience, observations of the experience of others, and written, verbal, or non-verbal information communicated during treatment. Not surprisingly, expectation in the clinical setting is strongly influenced by the attitude, affect, and communication style of the healthcare provider. While positive expectations can produce beneficial effects, negative information and experiences can lead to negative expectations, and consequently negative or nocebo effects. Key components identified and studied in the placebo and nocebo literature intersect with factors identified as barriers to quality care in the clinical setting for Black patients and other patients of color, including poor patient-clinician communication, medical mistrust, and perceived discrimination. Thus, in the context of discrimination and bias, the absence of placebo and presence of nocebo-generating influences in clinical settings could potentially reinforce racial and ethnic inequities in clinical outcomes and care. Healthcare inequities have consequences that ripple through the medical system, strengthening adverse short- and long-term outcomes. Here, we examine the potential for the presence of nocebo effects and absence of placebo effects to play a role in contributing to negative outcomes related to unequal treatment in the clinical encounter.

Indexed as

communicationhealth inequitiesmistrustperceived discriminationplacebo and nocebo effects

Identifiers

PMID35002881
PMCPMC8733207
OpenAlexW4200293556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.